[HTML][HTML] Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations
W Liang, X Wu, W Fang, Y Zhao, Y Yang, Z Hu, C Xue… - PloS one, 2014 - journals.plos.org
Background Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib,
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …
Front-line Therapy in Advanced Non–Small Cell Lung Cancer With Sensitive Epidermal Growth Factor Receptor Mutations: A Network Meta-analysis
XY Li, JZ Lin, SH Yu - Clinical Therapeutics, 2020 - Elsevier
Purpose Several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
were firmly established as front-line treatment for non–small cell lung cancer (NSCLC) that …
were firmly established as front-line treatment for non–small cell lung cancer (NSCLC) that …
Guide to Targeted Therapies: EGFR mutations in NSCLC
F Cappuzzo - 2014 - Springer
Non-small cell lung cancer (NSCLC) tumors with specific mutations in the epidermal growth
factor receptor (EGFR) tyrosine kinase have been defined as 'oncogene addicted'to indicate …
factor receptor (EGFR) tyrosine kinase have been defined as 'oncogene addicted'to indicate …
Pooled analysis of clinical outcome for EGFR TKI‐treated patients with EGFR mutation‐positive NSCLC
L Paz‐Ares, D Soulieres, J Moecks… - Journal of Cellular …, 2014 - Wiley Online Library
Patients with non‐small‐cell lung cancer (NSCLC) appear to gain particular benefit from
treatment with epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitors (TKI) if …
treatment with epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitors (TKI) if …
[HTML][HTML] Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non–Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and …
Guidance concerning tyrosine kinase inhibitors (TKIs) for patients with wild type epidermal
growth factor receptor (EGFR) and advanced non–small-cell lung cancer (NSCLC) after first …
growth factor receptor (EGFR) and advanced non–small-cell lung cancer (NSCLC) after first …
Comparison between second-and third-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with non-small-cell lung …
S Mitsuya, K Tsuruoka, K Kanaoka… - Anticancer …, 2021 - ar.iiarjournals.org
Background: For epidermal growth factor receptor (EGFR)-mutated non-small cell lung
cancer (NSCLC), administration of EGFR tyrosine kinase inhibitors (TKIs) is mandatory to …
cancer (NSCLC), administration of EGFR tyrosine kinase inhibitors (TKIs) is mandatory to …
Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb …
L Paz-Ares, EH Tan, L Zhang, V Hirsh… - Annals of …, 2016 - annalsofoncology.org
Background The irreversible ErbB family blocker, A, and the reversible EGFR TKI, G, are
approved for 1st-line treatment (tx) of advanced EGFRm+ NSCLC. In LL7, A (40 mg/d) …
approved for 1st-line treatment (tx) of advanced EGFRm+ NSCLC. In LL7, A (40 mg/d) …
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer
BC Liao, CC Lin, JCH Yang - Current opinion in oncology, 2015 - journals.lww.com
Second and third-generation epidermal growth factor receptor... : Current Opinion in Oncology
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in …
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in …
Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR …
T Payen, J Trédaniel, L Moreau, S Larivé… - … Medicine and Research, 2021 - Elsevier
Background Phase III clinical trials have demonstrated the merits of epidermal growth factor
receptor (EGFR)-tyrosine kinase inhibitors (TKI) in the treatment of non-small cell lung …
receptor (EGFR)-tyrosine kinase inhibitors (TKI) in the treatment of non-small cell lung …
[HTML][HTML] Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR …
Introduction Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …